STAT+: Abridge inks deals with Nvidia and Lilly
NEW YORK — Health care AI company Abridge on Thursday announced new deals with two trillion-dollar companies, pharma giant Eli Lilly and chip-maker Nvidia, as it aims to gain an edge in the competitive market that supports doctors and streamlines hospital billing and operations.
Draped head-to-toe in black, on a day forecast to be in the 90s, Abridge CEO Shiv Rao announced that Eli Lilly would make a strategic investment in the company. Abridge also announced a new partnership with Nvidia to develop “the first foundation model purpose-built for clinical conversations,” according to a release.
Abridge has disclosed nearly $800 million in funding and was most recently valued at over $5 billion. The company gained huge momentum for its ambient scribe that can listen to a conversation between a doctor and patient and draft a clinical note. The AI scribe technology has gained momentum, especially thanks to its ability to help health systems bill for services more efficiently and comprehensively.


























































































































































































